Cappelletty D M, Rybak M J
Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, Michigan 48201, USA.
Antimicrob Agents Chemother. 1996 Mar;40(3):677-83. doi: 10.1128/AAC.40.3.677.
The purpose of this study was to determine if synergism was maintained for various combinations of beta-lactams with an aminoglycoside against four clinical strains and one laboratory strain of Pseudomonas aeruginosa which were resistant, according to the MICs, to the beta-lactams and/or aminoglycoside. The results from both the checkerboard and killing curve methodologies were compared. The laboratory strain (ATCC 27853) was manipulated in vitro by serial passage onto agar containing increasing concentrations of each antibiotic to select for resistance. One clinical isolate (R61) was also serially passed to raise the MIC of piperacillin from 128 to 1,024 micrograms/ml. The fractional inhibitory concentration indices for all isolates indicated indifference for all combination therapies, with values ranging from 0.6 to 3. In contrast, killing curve results for all isolates demonstrated synergism with drug concentrations at either one-fourth or one-half the MIC for each organism. The MIC of piperacillin for the laboratory-manipulated clinical isolate R61 was 1,024 micrograms/ml, and synergism was still observed with concentrations of one-half the MIC of piperacillin and amikacin. For clinical isolate R166, which was beta-lactam and tobramycin resistant, synergism continued to be demonstrated with concentrations of tobramycin (1/16 MIC) in combination with piperacillin and cefepime at 1/2 the MIC. The results of this study indicate that against P. aeruginosa, synergism is observed in spite of resistance to beta-lactams and/or aminoglycosides. Synergism appears to be maintained even at very high MICs (piperacillin, 1,024 micrograms/ml; tobramycin, 128 micrograms/ml) with drug concentrations within achievable therapeutic ranges. With current definitions of synergism there was a complete lack of correlation between the results obtained by the checkerboard and killing curve methodologies, with the fractional inhibitory concentration indices showing indifference and killing curves resulting in synergism. The methodologies and definitions of synergism or antagonism are variable and not standardized and should be reevaluated.
本研究的目的是确定β-内酰胺类药物与氨基糖苷类药物的各种组合对4株临床分离株和1株铜绿假单胞菌实验室菌株是否保持协同作用,根据最低抑菌浓度(MIC),这些菌株对β-内酰胺类药物和/或氨基糖苷类药物耐药。比较了棋盘法和杀菌曲线法的结果。通过在含有浓度递增的每种抗生素的琼脂上连续传代,对实验室菌株(ATCC 27853)进行体外操作以选择耐药性。一株临床分离株(R61)也进行了连续传代,使哌拉西林的MIC从128微克/毫升提高到1024微克/毫升。所有分离株的部分抑菌浓度指数表明所有联合治疗方案均无协同作用,数值范围为0.6至3。相比之下,所有分离株的杀菌曲线结果显示,当药物浓度为每种菌株MIC的四分之一或二分之一时具有协同作用。实验室操作的临床分离株R61对哌拉西林的MIC为1024微克/毫升,当哌拉西林和阿米卡星的浓度为哌拉西林MIC的二分之一时,仍观察到协同作用。对于对β-内酰胺类药物和妥布霉素耐药的临床分离株R166,当妥布霉素浓度为1/16 MIC并与哌拉西林和头孢吡肟浓度为1/2 MIC联合使用时,仍显示出协同作用。本研究结果表明,对于铜绿假单胞菌,尽管对β-内酰胺类药物和/或氨基糖苷类药物耐药,但仍观察到协同作用。即使在非常高的MIC(哌拉西林,1024微克/毫升;妥布霉素,128微克/毫升)下,当药物浓度在可达到的治疗范围内时,协同作用似乎仍能维持。根据目前协同作用的定义,棋盘法和杀菌曲线法获得的结果之间完全缺乏相关性,部分抑菌浓度指数显示无协同作用,而杀菌曲线显示有协同作用。协同作用或拮抗作用的方法和定义各不相同且未标准化,应重新评估。